ACADEMIA

Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment

September 14, 2018
The use of Tagrisso (osimertinib) in front-line treatment would bring the biggest benefits to patients with EGFR-mutated lung cancer, Yuichiro Ohe, a prominent oncologist at the National Cancer Center (NCC), said on September 13, welcoming the first-line nod given to…

To read the full story

ACADEMIA

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…